drugset
drugset / Trial / NCT04941404

A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

NCT04941404 ↗

Phase 1/2 Terminated 13 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label,single arm,Phase Ib study,in order to evaluate the safety,tolerability, preliminary efficacy and pharmacokinetics of TQ05105 tablets in subjects with Glucocorticoid-Refractory aGVHD

Timeline

Start
2022-06-10
Primary completion
2023-07-10
Completion
2024-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject TQ05105 Small molecule 5 mg Oral
Subject TQ05105 Small molecule 10 mg Oral
Subject TQ05105 Small molecule 15 mg Oral

Indications

No indication recorded.